Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Appointed CFO

NANOVIRICIDES, INC. (NNVC) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/25/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "PLAN OF CONVERSION OF NANOVIRICIDES, INC."
03/31/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "LICENSE AGREEMENT THIS LICENSE AGREEMENT is made at Kolhapur on March 10, 2023 by and Between NANOVIRICIDES, INC. a Company incorporated under the laws of the State of Nevada, and having its registered office at 1 Controls Drive, Shelton, CT 06484 and its successors and assigns with offices And M/S KARVEER MEDITECH PRIVATE LIMITED a company incorporated under Companies Act, 2013 and having it registered office at plot No. 34, Vijaya Nagar, Near Shahu Naka, Ujalaiwadi, Kolhapur, Taluka-Karveer, District-Kolhapur, Maharashtra, India 416004 and its successors and assigns and all of whom are at times referred to as the "Parties". WHEREAS, Karveer is engaged in conducting research and development in the fields of pharmaceuticals and related activities, and has the necessary skill, experience, e..."
02/13/2023 8-K Quarterly results
12/22/2022 8-K Submission of Matters to a Vote of Security Holders, Other Events  Interactive Data
10/11/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "EXTENSION TO EMPLOYMENT AGREEMENT This Extension to Employment Agreement effective as of July 1, 2022, between ANIL R. DIWAN, c/o NanoViricides, Inc., 1 Controls Drive, Shelton, CT 06484 , and NanoViricides, Inc., a corporation with offices at 1 Controls Drive, Shelton, CT 06484 . WHEREAS, the Parties entered into that certain Employment Agreement on July 11, 2018 which expired pursuant to its terms on June 30, 2021 which was subsequently extended to June 30, 2022 ; WHEREAS, the parties hereto desire to extend the term of the Employment Agreement and to add to and/or revise the terms and conditions of the Employment Agreement; and WHEREAS, the Parties hereto desire that all other terms and conditions of the Employment Agreement not specifically amended hereby will remain in full force and ..."
11/26/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
09/21/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Draft Information Document"
09/15/2021 8-K Quarterly results
12/10/2020 8-K Submission of Matters to a Vote of Security Holders
11/19/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Form of Director Retainer Agreement",
"NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA"
09/04/2020 8-K Quarterly results
08/03/2020 8-K Quarterly results
07/13/2020 8-K Quarterly results
06/04/2020 8-K Resignation/termination of a director
05/22/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Opinion of McCarter & English LLP",
"Form of Securities Purchase Agreement by and between NanoViricides, Inc. and certain purchasers",
"Placement Agent Agreement, by and between among NanoViricides, Inc. Maxim Group LLC and Kingswood Capital Markets, a division of Benchmark Investments, Inc",
"NanoViricides Announces Pricing of $10.2 Million Registered Direct Offering Shelton, Connecticut -- May 21, 2020 -- NanoViricides, Inc. , a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has entered into a securities purchase agreement with several institutional investors for the issuance and sale of 1,400,000 shares of its common stock at a price of $7.30 per share, for aggregate gross proceeds of approximately $10.22 million, in a registered direct offering. Maxim Group LLC and Kingswood Capital Markets, a division of Benchmark Investments, Inc., are acting as co-placement agents for the offering. The offering is expected to close on or about May 22, 2020, subject to the satisfaction of customary closing ..."
05/19/2020 8-K Appointed a new director
Docs: "Director Retainer Agreement, between the Company and Mr. Rokita",
"Honorable Ex-Congressman Todd Rokita Joins the Board of Directors of NanoViricides, Inc. SHELTON, CONNECTICUT -- May 18, 2019 -- NanoViricides, Inc. , a leader in developing novel nanomedicines to treat viral diseases, announced today that Honorable Mr. Todd Rokita, J.D., former member of the U.S. House of Representatives from Indiana, has joined the Company’ s Board of Directors, effective May 15, 2020, as an independent director. He was also appointed as a member of the Board’ s Nomination Committee and Compensation Committee. Most recently, Mr. Rokita has been nominated by President Trump to the Board of Directors of the National Railroad Passenger Corporation , pending U.S. Senate Confirmation. He is currently co-owner and General Counsel and Vice President of External Affairs, Apex Be..."
05/14/2020 8-K Quarterly results
03/20/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Certificate of Amendment to Articles of Incorporation"
02/11/2020 8-K Quarterly results
01/28/2020 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of Settlement Agreement and Mutual Release",
"Form of Exchange Agreement",
"Form of Common Stock Purchase Agreement"
01/27/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Underwriting with Aegis Capital Corp.",
"NANOVIRICIDES CLOSES ON $8.625 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK SHELTON, CONNECTICUT — Friday, January 24, 2020 -- NanoViricides, Inc. a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has completed an underwritten public offering with gross proceeds of $8.625 million before deducting underwriting discounts and other estimated offering expenses. The Offering included 2.5 million shares of the Company’ s common stock, and 375,000 additional shares from the exercise of the underwriter’ s option to purchase to cover over-allotments at the public offering price of $3.00 per share. Aegis Capital Corp. acted as sole bookrunner for the offering. The net proceeds to the Company after unde..."
12/19/2019 8-K Quarterly results
12/13/2019 8-K Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "NanoViricides President Dr. Anil Diwan Provides Responses to Shareholder Questions at the Annual Meeting of Shareholders SHELTON, CONNECTICUT -- December 9, 2019 -- NanoViricides, Inc. , a global leader in nanomedicines against viruses, held its annual meeting of shareholders of the Company on Saturday, December 7th, 2019 at 10:00 a.m., Eastern Daylight Time. The meeting was held at the Sheraton Stamford Hotel, 700 East Main Street, Stamford Connecticut 06901. Upon adjournment of the business portion of the meeting, it was opened for questions from shareholders. In response to questions from shareholders regarding a timeline for the Company’ s first IND filing with the US FDA, Dr. Diwan reported that the timeline was extremely dependent on external collaborators, and as such, the Company c..."
11/05/2019 8-K Quarterly results
09/26/2019 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Certificate of Change pursuant to NRS Section 78.209 of NanoViricides, Inc"
08/01/2019 8-K Resignation/termination of a director
Docs: "Letter from Dr. Mukund Kulkarni"
06/10/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Director Retainer Agreement"
03/01/2019 8-K Quarterly results
02/01/2019 8-K Quarterly results
12/07/2018 8-K Submission of Matters to a Vote of Security Holders
10/31/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Director Retainer Agreement"
07/23/2018 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "A. Diwan Employment Agreement",
"I. Taraporewala Employment Agreement"
05/04/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office...
Docs: "Form of Warrant",
"Confidential Separation Agreement and General Release"
12/15/2017 8-K Submission of Matters to a Vote of Security Holders
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy